Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same

Patent metadata

Field	Value
Publication number	US-11753471-B2
Application number	US-201916968241-A
Country	US
Kind code	B2
Filing date	Feb 8, 2019
Priority date	Feb 8, 2018
Publication date	Sep 12, 2023
Grant date	Sep 12, 2023

Abstract

Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.

First claim

The invention claimed is:

1. A heterodimeric bispecific antibody comprising:
a first antigen-binding site capable of specifically binding to PD-1 (PD-1 antigen-binding site); and
a second antigen-binding site capable of specifically binding to HER2 (HER2 antigen-binding site),
wherein the bispecific antibody comprises a first Fc chain and a second Fc chain that are linked to each other via at least one disulfide bond,
wherein the first Fc chain and the second Fc chain are each linked to the PD-1 antigen-binding site and the HER2 antigen-binding site, respectively, via a covalent bond or a linking group, or the first Fc chain and the second Fc chain are each linked to the HER2 antigen-binding site and the PD-1 antigen-binding site, respectively, via a covalent bond or a linking group,
wherein an amino acid sequence of an immunoglobulin light chain variable region in the PD-1 antigen-binding site comprises the sequence of SEQ ID NO:10, an amino acid sequence of an immunoglobulin heavy chain variable region in the PD-1 antigen-binding site comprises the sequence of SEQ ID NO: 12,
wherein the first Fc chain and the second Fc chain comprise five amino acid substitutions selected from following (a)-(h):
(a) T366L and D399R substitutions of the first Fc chain and L351E, Y407L, and K409V substitutions of the second Fc chain;
(b) T366L and D399C substitutions of the first Fc chain and L351G, Y407L, and K409C substitutions of the second Fc chain;
(c) T366L and D399C substitutions of the first Fc chain and L351Y, Y407A, and K409P substitutions of the second Fc chain;
(d) T366P and D399N substitutions of the first Fc chain and L351V, Y407P, and K409S substitutions of the second Fc chain;
(e) T366W and D399G substitutions of the first Fc chain and L351D, Y407P, and K409S substitutions of the second Fc chain;
(f) T366P and D399I substitutions of the first Fc chain and L351P, Y407F, and K409F substitutions of the second Fc chain;
(g) T366V and D399T substitutions of the first Fc chain and L351K, Y407T, and K409Q substitutions of the second Fc chain; or
(h) T366L and D399A substitutions of the first Fc chain and L351W, Y407H, and K409R substitutions of the second Fc chain, and
wherein amino acid positions in the above (a)-(h) are numbered according to the Kabat EU Index Numbering System.

2. The heterodimeric bispecific antibody of claim 1 , wherein the five amino acid substitutions are (a) T366L and D399R substitutions of the first Fc chain, and L351E, Y407L, and K409V substitutions of the second Fc chain.

3. The heterodimeric bispecific antibody of claim 1 , wherein the first and the second Fc chains are derived from immunoglobulin G (IgG).

4. The heterodimeric bispecific antibody of claim 1 , wherein the PD-1 antigen-binding site and the HER2 antigen-binding site are each a Fab fragment or an scFv fragment.

5. The heterodimeric bispecific antibody of claim 4 , wherein the Fab fragment comprises different first and second heavy chain variable regions and different first and second light chain variable regions.

6. The heterodimeric bispecific antibody of claim 1 , wherein the PD-1 antigen-binding site and the HER2 antigen-binding site are each a Fab fragment, or one selected from the PD-1 antigen-binding site and the HER2 antigen-binding site is a Fab fragment, and the other is an scFv fragment.

7. The heterodimeric bispecific antibody of claim 1 , wherein, when each of the first Fc chain covalently bonded to the PD-1 antigen binding region and the second Fc chain covalently bonded to the HER2 antigen binding region, or each of the first Fc chain covalently bonded to the HER2 antigen binding region and the second Fc chain covalently bonded to the PD-1 antigen binding region, is present alone in the presence of a reducing agent, the weight ratio of the constituent homodimers are smaller than 50%.

8. The heterodimeric bispecific antibody of claim 1 , wherein the HER2 antigen-binding site of the bispecific antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6.

9. A composition comprising the heterodimeric bispecific antibody of claim 1 , and a pharmaceutically acceptable carrier.

Assignees

• Beijing Hanmi Pharmaceutical Co Ltd
• Innovent Biologics Suzhou Co Ltd

Inventors

• Liu Jiawang
• Song Nanmeng
• Yang Yaping
• Kim Maeng Sup
• Yan Yao
• Yin Qingqing

Classifications

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title

• C07K16/32 Primary

  against translation products of oncogenes · CPC title

• C12N15/85

  for animal cells · CPC title

• C12N5/0682

  Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609) · CPC title

• C12N5/0686

  Kidney cells · CPC title